Tapentadol Depot G.L. Pharma
Low-dose extended-release opioid analgesic (25 mg) for severe chronic pain
Tapentadol Depot G.L. Pharma 25 mg is a strong, centrally acting opioid pain medication formulated as an extended-release tablet. It is used for the treatment of severe chronic pain in adults when non-opioid analgesics are no longer sufficient. Tapentadol has a unique dual mechanism — it activates mu-opioid receptors and inhibits norepinephrine reuptake — providing steady pain relief over approximately 12 hours. The 25 mg strength is the lowest depot dose available and is particularly useful for cautious initiation of opioid therapy, for elderly or frail patients, and for fine-tuning doses during titration. This is a prescription-only, controlled-substance medicine that must be used under close medical supervision.
Quick Facts
Key Takeaways
- Tapentadol Depot G.L. Pharma 25 mg is a strong opioid extended-release tablet prescribed for severe chronic pain that does not respond to non-opioid analgesics. The 25 mg strength is the lowest depot dose, designed for gentle initiation of therapy.
- The extended-release tablets must be swallowed whole every 12 hours. Never crush, chew, or break them, as this can cause a life-threatening overdose from rapid drug release.
- Tapentadol has a dual mechanism of action (mu-opioid receptor agonism plus norepinephrine reuptake inhibition), which may reduce certain opioid-related side effects such as constipation and nausea compared with pure mu-opioid agonists.
- Common side effects include nausea, constipation, dizziness, and drowsiness. Serious risks include respiratory depression, addiction, seizures, and serotonin syndrome when combined with serotonergic drugs.
- Do not combine with MAO inhibitors, benzodiazepines, alcohol, or other central nervous system depressants without medical guidance, as these combinations can be fatal.
What Is Tapentadol Depot G.L. Pharma and What Is It Used For?
Tapentadol Depot G.L. Pharma contains the active substance tapentadol, which belongs to the class of strong opioid analgesics. Unlike traditional opioids such as morphine or oxycodone, tapentadol has a unique dual mechanism of action known as MOR-NRI (mu-opioid receptor agonism combined with norepinephrine reuptake inhibition). This means it works through two complementary pain pathways in the central nervous system simultaneously, which may provide effective pain relief at lower opioid-equivalent doses.
The mu-opioid receptor agonism component modulates pain signals in the brain and spinal cord by activating the same receptors targeted by other opioids. The norepinephrine reuptake inhibition component enhances the descending pain inhibitory pathways, which are the body's natural pain-suppression system. By engaging both mechanisms, tapentadol can provide meaningful analgesia while potentially causing fewer gastrointestinal side effects (such as constipation and nausea) compared to equianalgesic doses of traditional pure mu-opioid agonists.
The extended-release (depot) formulation is specifically engineered to release tapentadol gradually over approximately 12 hours, providing steady, round-the-clock pain relief. This makes it suitable for chronic pain conditions that require continuous, long-term opioid therapy rather than intermittent or rescue dosing. The 25 mg strength is the lowest available depot dose and plays an important role in several clinical situations:
- Opioid-naive patients: Patients who have not previously received strong opioid therapy benefit from the lowest possible starting dose to minimize initial side effects such as nausea, dizziness, and somnolence.
- Elderly and frail patients: Older adults are more sensitive to opioid effects, and 25 mg provides a gentle entry point to therapy while allowing tolerance and efficacy to be assessed safely.
- Dose titration and fine-tuning: When clinicians need to adjust pain control precisely, the 25 mg strength allows for smaller increments between steady-state target doses.
- Opioid rotation: When switching from another opioid, the 25 mg dose facilitates conservative conversion, which reduces the risk of under- or over-treatment during the transition.
- Tapering: During gradual discontinuation after long-term therapy, the 25 mg strength enables slower, more tolerable dose reductions.
It is important to understand that tapentadol is reserved for patients whose pain is genuinely severe and has not responded adequately to non-opioid treatments such as paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), or adjuvants (for example antidepressants or anticonvulsants used for neuropathic pain). It is not intended for mild or intermittent pain, for acute post-operative pain management (where immediate-release formulations may be more appropriate), or as a first-line analgesic. Your prescribing physician will have determined that the benefits of tapentadol therapy outweigh the substantial risks associated with long-term opioid use.
Tapentadol Depot G.L. Pharma is marketed by G.L. Pharma GmbH, an Austrian pharmaceutical company that produces a range of generic prescription medicines. Generic medicines such as this contain the same active ingredient and are therapeutically equivalent to the original reference product, but are typically available at a lower cost to healthcare systems and patients.
Tapentadol extended-release formulations are authorized across the European Union, United Kingdom, United States (as a Schedule II controlled substance), Australia, Canada, and many other jurisdictions. Regulatory authorities including the EMA, FDA, and MHRA have approved tapentadol for severe chronic pain in adults, with specific conditions of use tailored to each region. The exact indication wording for Tapentadol Depot G.L. Pharma is determined by the national regulatory authority where it is marketed.
What Should You Know Before Taking Tapentadol Depot G.L. Pharma?
Before starting tapentadol therapy, your doctor will review your full medical history and current medications. Several conditions make the medicine unsuitable (contraindications), while others require careful monitoring or dose adjustments (precautions). Being honest and comprehensive with your healthcare team is essential — even over-the-counter products and herbal supplements can interact dangerously with opioids.
Contraindications
You must not take Tapentadol Depot G.L. Pharma if any of the following apply to you:
- Hypersensitivity to tapentadol or any other ingredient of the tablet. Signs of hypersensitivity include rash, swelling of the face or tongue, difficulty breathing, and severe itching.
- Severe respiratory depression — if your breathing is dangerously slow or shallow, or if you have hypercapnia (elevated carbon dioxide in the blood) in unmonitored settings. Tapentadol further suppresses the respiratory drive and can cause fatal respiratory arrest in these patients.
- Bronchial asthma that is acute or severe, particularly in the absence of resuscitation equipment or monitoring.
- Paralytic ileus — a condition in which the bowel has stopped functioning. Opioids slow gut motility further and can worsen this dangerous condition.
- Acute intoxication with alcohol, sleeping pills, other opioid analgesics, or psychotropic drugs (medications that affect mood and emotions). The combination of central nervous system depressants with tapentadol can be lethal.
- Concurrent use of monoamine oxidase (MAO) inhibitors or use within the previous 14 days. The interaction between tapentadol and MAO inhibitors can cause serotonin syndrome, hypertensive crisis, or cardiovascular collapse.
- Severe hepatic (liver) impairment — tapentadol elimination is significantly reduced, increasing the risk of toxicity.
- Severe renal (kidney) impairment — accumulation of metabolites may occur.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Tapentadol Depot G.L. Pharma if any of the following conditions apply to you:
- Respiratory conditions: Slow or shallow breathing, chronic obstructive pulmonary disease (COPD), cor pulmonale (right-heart strain from lung disease), or other conditions that compromise respiratory function. Tapentadol may cause life-threatening respiratory depression, particularly in elderly or debilitated patients. Starting at the 25 mg strength reduces this risk compared to higher starting doses.
- Sleep-disordered breathing: Obstructive sleep apnea or central sleep apnea may be worsened by opioids, and opioids can cause new-onset sleep-disordered breathing.
- Raised intracranial pressure or impaired consciousness: Including head injury, brain tumors, or reduced level of consciousness. Opioids can obscure the clinical course of patients with head injuries and may increase intracranial pressure.
- Moderate liver disease: Patients with moderate hepatic impairment require dose adjustment and a longer dosing interval. Severe hepatic impairment is an absolute contraindication.
- Moderate kidney disease: While no dose adjustment is required for mild or moderate renal impairment, such patients should still be monitored closely. Severe renal impairment is a contraindication.
- Pancreatic or biliary tract disease: Including pancreatitis. Opioids can cause spasm of the sphincter of Oddi, worsening biliary conditions and potentially triggering pancreatitis.
- Seizure disorders or epilepsy: Tapentadol may lower the seizure threshold, especially when combined with other medications that increase seizure risk (such as certain antidepressants or antipsychotics). Patients with uncontrolled epilepsy should generally not receive tapentadol.
- History of substance abuse: If you or a family member has ever misused or been dependent on alcohol, prescription medications, or illegal drugs, you are at increased risk of developing opioid use disorder. Inform your doctor honestly about your full history.
- Mental health conditions: Depression, anxiety, post-traumatic stress disorder, personality disorders, or other psychiatric conditions may increase the complexity of opioid management and the risk of misuse.
- Endocrine disorders: Long-term opioid use can cause adrenal insufficiency and reduced sex hormone levels (hypogonadism). Symptoms include fatigue, decreased libido, erectile dysfunction, menstrual irregularities, and loss of muscle mass.
Tapentadol is a controlled substance opioid. Repeated use can lead to tolerance (needing higher doses for the same effect), physical dependence (experiencing withdrawal symptoms if stopped abruptly), and addiction (compulsive drug-seeking behavior). Even use at prescribed therapeutic doses carries risk. Starting at the lowest effective dose — such as the 25 mg strength — and regularly reassessing whether continued therapy is providing meaningful benefit are key strategies to minimize these risks. If you believe you are developing dependence, contact your doctor immediately. Do not attempt to stop abruptly on your own.
Tapentadol can cause sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low blood oxygen during sleep). Symptoms may include witnessed breathing pauses during sleep, frequent nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime drowsiness. If you or someone observing you notices these symptoms, contact your doctor, who may consider a dose reduction or further evaluation with a sleep study.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Tapentadol Depot G.L. Pharma. The following precautions apply:
- Pregnancy: Tapentadol should not be used during pregnancy unless your doctor has specifically determined it is necessary. Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS) in the newborn. NOWS can be life-threatening if not recognized and treated promptly. Symptoms in the newborn include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremor, vomiting, diarrhea, and failure to gain weight. Newborns of mothers who have taken opioids during pregnancy should be monitored in a hospital setting capable of treating NOWS.
- Labor and delivery: Tapentadol should not be used during childbirth, as it can cause dangerously slow or shallow breathing (respiratory depression) in the newborn.
- Breastfeeding: Tapentadol may be excreted in breast milk and could affect the nursing infant. Breastfeeding is generally not recommended while taking this medication.
- Fertility: Long-term opioid use may reduce fertility in both men and women through effects on sex hormone production. This is generally reversible after stopping the medication.
Driving and Operating Machinery
Tapentadol Depot G.L. Pharma can cause drowsiness, dizziness, and blurred vision, and may impair your reaction time. These effects are most pronounced when starting treatment, during dose changes, or when combined with alcohol or sedative medications. Do not drive, operate heavy machinery, or perform activities requiring alertness until you know how this medication affects you. Starting at 25 mg provides an opportunity to assess your individual sensitivity before considering any dose increase. Your doctor will advise you on whether it is safe for you to drive, and in some jurisdictions there are legal restrictions on driving while taking opioid analgesics.
How Does Tapentadol Depot G.L. Pharma Interact with Other Drugs?
Drug interactions with tapentadol can be dangerous and even fatal. The dual mechanism of action (opioid agonism and norepinephrine reuptake inhibition) creates interaction potential with a broader range of medications than traditional opioids. Interactions occur most commonly at the level of the central nervous system (additive sedation and respiratory depression) and serotonin/norepinephrine neurotransmission (serotonin syndrome risk). It is essential that your doctor and pharmacist know about every medication you take, including prescription drugs, over-the-counter products, vitamins, and herbal remedies.
Major Interactions (Potentially Life-Threatening)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| MAO inhibitors (e.g., phenelzine, tranylcypromine, selegiline, moclobemide) | Serotonin syndrome, hypertensive crisis, cardiovascular collapse | Absolutely contraindicated. Do not use within 14 days of MAO inhibitor therapy. |
| Benzodiazepines (e.g., diazepam, lorazepam, alprazolam, clonazepam) | Profound sedation, respiratory depression, coma, death | Avoid combination. If unavoidable, use lowest doses for shortest duration with close monitoring. |
| Other opioids (e.g., morphine, codeine, tramadol, oxycodone, fentanyl) | Additive respiratory depression, overdose | Generally avoid. Careful dose adjustment if a temporary overlap is clinically necessary (e.g., opioid rotation). |
| Alcohol (including in medicines and mouthwashes) | Enhanced CNS depression, respiratory depression, fatal overdose | Absolutely avoid alcohol during treatment. |
| Serotonergic drugs (e.g., SSRIs, SNRIs, tricyclic antidepressants, triptans, St. John's Wort) | Serotonin syndrome — agitation, hyperthermia, myoclonus, autonomic instability | Use with extreme caution. Monitor for serotonin syndrome symptoms, especially when starting or changing doses. |
| Gabapentinoids (gabapentin, pregabalin) | Increased risk of opioid overdose, respiratory depression, death | Use lowest effective doses of both medications. Close monitoring required, particularly when initiating or escalating therapy. |
Moderate Interactions
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| Sedating antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine) | Additive sedation, respiratory depression | Use with caution. Monitor for excessive sedation, especially when starting. |
| Barbiturates (e.g., phenobarbital) | Additive CNS depression; phenobarbital may also induce tapentadol metabolism | Avoid if possible. Dose adjustment may be needed. |
| Antipsychotics (e.g., haloperidol, quetiapine, olanzapine) | Additive sedation, lowered seizure threshold, QT prolongation with some agents | Monitor closely. Be alert for seizures and excessive sedation. |
| Mixed agonists/antagonists (pentazocine, nalbuphine) or partial agonists (buprenorphine) | Reduced efficacy of tapentadol; potential precipitated opioid withdrawal | Avoid combination. May diminish analgesic effect or provoke withdrawal. |
| Strong enzyme inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort) | Reduced tapentadol efficacy due to accelerated metabolism | Inform your doctor. Dose adjustment may be needed. Abrupt discontinuation of an inducer may increase tapentadol levels. |
| Seizure-lowering drugs (e.g., bupropion, tramadol, certain antipsychotics) | Increased seizure risk | Use with caution. Monitor for seizure activity, especially in patients with a history of epilepsy. |
| Diuretics | Opioids may reduce effectiveness of diuretics by inducing antidiuretic hormone release | Monitor response; diuretic dose adjustment may be required. |
When combining tapentadol with serotonergic medications, watch for symptoms of serotonin syndrome: involuntary rhythmic muscle contractions (myoclonus), agitation, excessive sweating, tremor, exaggerated reflexes (hyperreflexia), increased muscle tension, and body temperature above 38°C (100.4°F). Additional features may include confusion, rapid heart rate, unstable blood pressure, and dilated pupils. Serotonin syndrome is rare but potentially life-threatening. Seek immediate medical attention if you experience these symptoms.
Always inform your healthcare team about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements such as St. John's Wort. Some combinations that seem harmless can be dangerous when combined with tapentadol. Keep an up-to-date medication list and share it with every healthcare professional who treats you.
What Is the Correct Dosage of Tapentadol Depot G.L. Pharma?
Always take Tapentadol Depot G.L. Pharma exactly as your doctor or pharmacist has instructed. The guiding principle of opioid therapy is to use the lowest effective dose for the shortest necessary duration. The 25 mg extended-release strength is specifically designed to support this principle, enabling careful individual titration.
Adults
Standard Adult Dosing
- Starting dose (opioid-naive patients): 25 mg tapentadol every 12 hours (50 mg total daily dose)
- Titration: Your doctor may increase the dose gradually, typically in 25 mg or 50 mg increments per 12-hour dose, every 3 days, until adequate pain control is achieved.
- Maximum total daily dose: 500 mg (e.g., 250 mg twice daily). Higher doses are not recommended.
- Regular review: The continued need for tapentadol should be reassessed at regular intervals.
- If you feel the tablets are too strong or too weak, talk to your doctor — do not adjust the dose yourself.
Elderly Patients
Elderly Dosing (over 65 years)
- Dose adjustment is generally not required based on age alone, but elderly patients benefit from starting at the lowest available strength (25 mg).
- Excretion of tapentadol may be delayed in some elderly patients, and the doctor may recommend a longer dosing interval.
- Elderly patients are more susceptible to respiratory depression, falls, confusion, and urinary retention and should be closely monitored.
- Coexisting conditions (renal or hepatic impairment, cognitive impairment, polypharmacy) are common in this population and should inform dosing decisions.
Children and Adolescents
Pediatric Dosing
- The safety and efficacy of Tapentadol Depot G.L. Pharma in children and adolescents under 18 years have not been established for all indications and formulations. Use in this age group should only occur under specialist supervision and in line with local regulatory approvals.
- Tapentadol is not suitable for children under 2 years, and some formulations are not approved below 6 years.
- Children and adolescents with obesity should be monitored carefully; do not exceed recommended maximum doses.
- Children and adolescents with significant liver or kidney problems should not take these tablets.
Patients with Organ Impairment
| Condition | Recommendation |
|---|---|
| Mild hepatic impairment | No dose adjustment necessary; consider starting at 25 mg with conservative titration |
| Moderate hepatic impairment | Longer dosing interval recommended by your doctor (e.g., 25 mg every 24 hours), with careful monitoring |
| Severe hepatic impairment | Do not use — contraindicated |
| Mild/moderate renal impairment | No dose adjustment necessary; monitor for accumulation |
| Severe renal impairment | Do not use — contraindicated |
How to Take the Tablets
Tapentadol Depot G.L. Pharma tablets are taken orally (by mouth). Follow these important instructions:
- Swallow whole with a sufficient amount of liquid (e.g., a full glass of water). Do not crush, chew, break, or dissolve the tablets.
- The tablets can be taken with or without food — food does not significantly affect the medication's efficacy.
- Take the tablets at approximately the same times each day (every 12 hours) for consistent pain relief. Setting alarms or pairing dosing with regular daily activities can help with adherence.
- The tablet shell may occasionally appear in your stool. This is harmless — the active ingredient has already been absorbed through the extended-release matrix.
Crushing, chewing, or breaking the extended-release tablet destroys the controlled-release mechanism and can release the entire dose at once. This can cause a fatal overdose, even in patients who are tolerant to opioids. Tablet tampering has been implicated in many opioid-related deaths worldwide. Always swallow the tablet whole. If you have difficulty swallowing tablets, speak to your doctor — alternative formulations may be considered.
Missed Dose
If you forget to take a dose, you will likely notice your pain returning. Do not take a double dose to make up for the missed one, as this can cause dangerous side effects. Simply take your next dose at the regular time and continue your usual schedule. If you frequently forget doses, consider using reminder aids or a weekly pill organizer, and discuss strategies with your healthcare team.
Overdose
If you have taken too much Tapentadol Depot G.L. Pharma, or if a child or other person has accidentally ingested the medication, seek emergency medical help immediately by calling your local poison control center or emergency services. Do not wait for symptoms to develop.
Symptoms of opioid overdose may include:
- Pinpoint pupils (miosis)
- Nausea and vomiting
- Drop in blood pressure (hypotension)
- Rapid heartbeat (tachycardia) or, in severe cases, slow heart rate
- Circulatory collapse
- Reduced consciousness, profound drowsiness, or coma
- Seizures
- Dangerously slow or shallow breathing, or complete respiratory arrest
- Blue lips or fingertips (cyanosis) from lack of oxygen
Respiratory depression is the primary cause of opioid overdose deaths. The opioid antagonist naloxone can reverse respiratory depression caused by tapentadol, but medical supervision is still essential because the effects of naloxone may wear off before the effects of tapentadol, requiring repeated doses. In many countries, naloxone is available without a prescription or through community distribution programs, and patients on long-term opioid therapy or their family members may be advised to have naloxone on hand.
Stopping Treatment
Do not stop taking Tapentadol Depot G.L. Pharma suddenly without consulting your doctor. After prolonged use, abrupt discontinuation can cause opioid withdrawal symptoms including:
- Restlessness, watery eyes, runny nose, yawning, sweating, chills, gooseflesh (piloerection)
- Muscle aches, dilated pupils, irritability, anxiety, dysphoria
- Back pain, joint pain, generalized weakness, abdominal cramps
- Insomnia, nausea, loss of appetite, vomiting, diarrhea
- Increased blood pressure, increased respiratory rate, increased heart rate
- Craving for the medication
Your doctor will guide you through a gradual dose reduction (tapering) to minimize withdrawal symptoms. The 25 mg strength is particularly useful in the final stages of tapering, enabling slow, controlled reduction. The tapering schedule will be individualized based on your dose, duration of use, and other clinical factors. A typical approach might involve reducing the total daily dose by 10–25% every 1–4 weeks, with slower reductions toward the end of the taper.
What Are the Side Effects of Tapentadol Depot G.L. Pharma?
Like all medicines, Tapentadol Depot G.L. Pharma can cause side effects, although not everybody experiences them. The side effect profile is consistent with its opioid mechanism of action. Many common side effects improve as your body adjusts to the medication over the first few days to weeks of treatment. The 25 mg extended-release tablet is designed to provide a gentler introduction to opioid therapy, and it is often chosen specifically because higher starting doses cause excessive nausea or drowsiness.
Allergic reactions (wheezing, difficulty breathing, swelling of eyelids, face, lips, or tongue, widespread rash or itching), breathing that is slower or weaker than expected, severe chest pain, seizures, or symptoms of serotonin syndrome (agitation, fever, muscle rigidity, confusion). These require emergency medical care — call your local emergency number without delay.
Very Common
May affect more than 1 in 10 people
- Nausea
- Constipation
- Dizziness
- Drowsiness (somnolence)
- Headache
Common
May affect up to 1 in 10 people
- Decreased appetite
- Anxiety, depressed mood, sleep problems, nervousness, restlessness
- Attention disturbance, tremor, involuntary muscle twitching
- Flushing, shortness of breath
- Vomiting, diarrhea, digestive discomfort
- Itching, increased sweating, skin rash
- Feeling of weakness, fatigue, feeling of altered body temperature
- Dry mucous membranes, fluid retention (edema)
- Dry mouth
Uncommon
May affect up to 1 in 100 people
- Allergic reactions (including angioedema, urticaria, severe anaphylaxis)
- Weight loss, disorientation, confusion, agitation
- Perception difficulties, abnormal dreams, euphoria
- Reduced consciousness, memory impairment, mental impairment
- Fainting (syncope), sedation, balance problems, speech difficulties
- Numbness, abnormal skin sensations (tingling, prickling)
- Visual disturbances, increased/decreased heart rate, palpitations
- Decreased blood pressure, abdominal discomfort, urticaria
- Urinary retention, frequent urination, sexual dysfunction
- Drug withdrawal symptoms, feeling abnormal, irritability
Rare
May affect up to 1 in 1,000 people
- Drug dependence
- Abnormal thinking
- Seizures (epileptic fits)
- Pre-syncope (feeling faint), abnormal coordination
- Respiratory depression (dangerously slow or shallow breathing)
- Impaired gastric emptying
- Feeling of intoxication, feeling of relaxation
- Serotonin syndrome (particularly with serotonergic co-medication)
Constipation is one of the most persistent opioid side effects and rarely improves without treatment. Your doctor may prescribe a stimulant laxative prophylactically. Nausea typically resolves within the first 1–2 weeks; antiemetics can help during this period. Drowsiness often diminishes as tolerance develops; if it persists, a dose adjustment may be needed. Dry mouth can be managed with frequent sips of water, sugar-free lozenges, or saliva substitutes.
Delirium has been reported with unknown frequency, particularly in elderly patients and those with underlying cognitive impairment. Additionally, patients with chronic pain may have an increased risk of suicidal thoughts and behavior. While certain medications that affect neurotransmitters (such as some antidepressants) can increase this risk, clinical data for tapentadol in humans do not show evidence of increased suicidal risk attributable to the drug itself.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. Reporting suspected adverse reactions after marketing authorization is important for ongoing monitoring of the medicine's benefit-risk balance. In most countries, patients and healthcare professionals can report adverse reactions to the national pharmacovigilance authority.
How Should You Store Tapentadol Depot G.L. Pharma?
Proper storage of opioid medications is critically important for safety, particularly in households with children, adolescents, or individuals at risk of substance misuse. Tapentadol Depot G.L. Pharma tablets should be stored in their original packaging, which provides protection from moisture and light and often incorporates child-resistant features such as safety-sealed closures or individual blisters.
- Keep out of the sight and reach of children. Accidental ingestion by a child can be fatal. Even one tablet can cause life-threatening respiratory depression in a young child.
- Do not use after the expiry date stated on the packaging (after “EXP”). The expiry date refers to the last day of that month.
- Store at room temperature, below 25°C (77°F), unless otherwise stated on the packaging. Do not refrigerate or freeze.
- Keep the tablets in their original packaging until use to protect them from moisture.
- Disposal: Do not flush unused medications down the toilet or throw them in household waste. Return unused tablets to your pharmacy for safe disposal. This protects the environment and prevents accidental exposure or diversion.
- Secure storage: Consider storing opioids in a locked cabinet or lockbox, especially if there are children, teenagers, visitors, or individuals with a history of substance use disorders in the home.
If you have leftover medication after completing treatment, dispose of it promptly. Keeping unused opioids in the home increases the risk of accidental ingestion, theft, or misuse. Many pharmacies and local authorities offer take-back programs for safe medication disposal; your pharmacist can direct you to the nearest facility. If take-back options are unavailable, specific disposal instructions from regulatory authorities (such as the FDA flush list or EMA guidelines) should be followed.
What Does Tapentadol Depot G.L. Pharma Contain?
Active Ingredient
Each extended-release tablet contains 25 mg of tapentadol (as tapentadol hydrochloride). The drug is embedded in a polymer matrix that releases the active ingredient gradually over approximately 12 hours when the tablet is swallowed whole.
Inactive Ingredients (Excipients)
The exact composition of excipients may vary by country of marketing and batch, but typically includes:
Tablet core: Hypromellose (a sustained-release polymer), microcrystalline cellulose, colloidal anhydrous silicon dioxide, and magnesium stearate.
Film coating: Hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol (polyethylene glycol), triacetin, and strength-specific iron oxide colorants. The exact color and imprint of the 25 mg tablet is specified in the product-specific patient information leaflet supplied with the medication.
Tapentadol Depot G.L. Pharma tablets typically contain lactose monohydrate as an excipient in the film coating. If you have been told by your doctor that you have an intolerance to some sugars, or if you have congenital lactase deficiency or glucose-galactose malabsorption, consult your doctor before taking this medicine.
Pack Sizes
Tapentadol Depot G.L. Pharma 25 mg tablets are typically supplied in blister packs or high-density polyethylene (HDPE) bottles with child-resistant closures. Common pack sizes include 20, 28, 30, 50, 56, 60, or 100 tablets. Not all pack sizes may be marketed in all countries. Your pharmacist will dispense the pack size prescribed by your doctor; for chronic therapy, larger packs may be more economical, while smaller packs are often preferred at treatment initiation.
Marketing Authorization Holder and Manufacturer
Tapentadol Depot G.L. Pharma is manufactured and marketed by G.L. Pharma GmbH, headquartered in Lannach, Austria. G.L. Pharma is a long-established European pharmaceutical manufacturer producing a range of generic prescription medicines, with particular expertise in controlled substances and pain medications. Generic products are required to demonstrate bioequivalence to the originator (reference) product, ensuring therapeutic equivalence.
Frequently Asked Questions
Tapentadol Depot G.L. Pharma 25 mg is prescribed for the management of severe chronic pain in adults when non-opioid pain medications have proven insufficient. The 25 mg strength is the lowest available depot dose and is particularly useful for starting opioid therapy in patients who have not previously taken strong opioids, for elderly or frail patients who require careful titration, and for precise dose adjustment during ongoing treatment. Common conditions for which it may be prescribed include severe chronic musculoskeletal pain, cancer-related pain, and chronic neuropathic pain requiring opioid-level analgesia.
The 25 mg extended-release strength is the lowest depot formulation of tapentadol and serves several important clinical purposes. First, it allows cautious initiation of opioid therapy in opioid-naive patients, minimizing the severity of initial side effects such as nausea, dizziness, and drowsiness. Second, it enables fine-grained dose titration, giving clinicians more flexibility to find the individually appropriate maintenance dose. Third, it supports safe and comfortable tapering during treatment discontinuation. Finally, it is often preferred in elderly or frail patients, who are more sensitive to opioid effects and benefit from the lowest possible effective dose.
Tapentadol is unique among opioids because it has a dual mechanism of action: mu-opioid receptor agonism (like traditional opioids) combined with norepinephrine reuptake inhibition (similar to certain antidepressants used for neuropathic pain). This dual mechanism allows tapentadol to provide effective pain relief through two complementary pathways. Clinical studies suggest that this may result in fewer gastrointestinal side effects (especially constipation and nausea) at equivalent analgesic doses compared to pure mu-opioid agonists like morphine or oxycodone. The norepinephrine reuptake inhibition component also makes tapentadol theoretically attractive for chronic pain with neuropathic features.
The extended-release tablet is designed with a special matrix that slowly releases the medication over 12 hours. If you crush, chew, or break the tablet, you destroy this controlled-release mechanism. The entire 12-hour dose of tapentadol would then be absorbed rapidly, potentially leading to a massive overdose. This can cause fatal respiratory depression (your breathing stops) even in individuals who are already tolerant to opioids. Always swallow the tablet whole with liquid. If you have difficulty swallowing tablets, tell your doctor — alternative formulations may be available.
No. Alcohol must be completely avoided while taking Tapentadol Depot G.L. Pharma. Alcohol is a central nervous system depressant, and combining it with tapentadol can dramatically increase the risk of life-threatening respiratory depression, profound sedation, coma, and death. Even moderate amounts of alcohol can significantly amplify the dangerous effects of opioids. This includes beer, wine, spirits, and alcohol-containing medications or mouthwashes. Alcohol can also cause the extended-release matrix in some formulations to break down more quickly (dose dumping), releasing the drug faster than intended.
If you suspect an overdose, call your local emergency services or poison control center immediately. Symptoms of overdose include pinpoint pupils, vomiting, low blood pressure, slow or absent breathing, loss of consciousness, and seizures. While waiting for emergency help, try to keep the person awake and breathing, and place them in the recovery position if they are unconscious but breathing. If available, naloxone (an opioid reversal agent) can be administered by mouth spray or injection. Even after naloxone, emergency medical care is still essential because the effects of tapentadol can outlast those of naloxone, requiring repeated doses.
No, you should not stop taking tapentadol abruptly after prolonged use, as this can trigger withdrawal symptoms including restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle aches, anxiety, insomnia, nausea, vomiting, and diarrhea. The 25 mg strength is particularly useful during gradual tapering, allowing for small, tolerable dose reductions over time. Your doctor will create a personalized tapering plan based on your dose, duration of use, and individual response. Always discuss any desire to stop treatment with your doctor first.
References
This article is based on the following evidence-based sources:
- European Medicines Agency (EMA). Tapentadol — Summary of Product Characteristics (SmPC). Available at: ema.europa.eu.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents (2018). Geneva: WHO.
- Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. “Is tapentadol different from classical opioids? A review of the evidence.” British Journal of Pain. 2016;10(4):217–221.
- Tzschentke TM, et al. “Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.” Drugs of Today. 2009;45(7):483–496.
- National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE guideline [NG193]. 2021.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- Kress HG. “Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally acting analgesics on the horizon?” European Journal of Pain. 2010;14(8):781–783.
- British National Formulary (BNF). Tapentadol monograph. Available at: bnf.nice.org.uk.
- U.S. Food and Drug Administration (FDA). Full Prescribing Information for tapentadol extended-release. Available at: fda.gov.
- International Association for the Study of Pain (IASP). Position statement on the use of opioid analgesics in the management of chronic non-cancer pain. 2018.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in pain medicine, clinical pharmacology, and evidence-based medicine.
iMedic Medical Editorial Team — specialists in pharmacology and pain medicine with clinical and academic expertise.
iMedic Medical Review Board — independent panel of board-certified physicians reviewing all content against international guidelines (EMA, WHO, FDA, NICE, BNF).
Editorial Standards: All medication information follows the GRADE evidence framework and is cross-referenced with the European Medicines Agency SmPC, WHO guidelines, and current peer-reviewed literature. No commercial funding or pharmaceutical sponsorship influences our content. Read more about our editorial standards.